The first available CAR T-cell therapy in MM was idecabtagene vicleucel (ide-cel) based initially on the results of the KarMMa trial [3], investigating the efficacy of ide-cel in patients with at least three prior lines of therapy including a proteasome inhibitor (PI), immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody (mAb). The gene discussed is CD38; the disease is Miyoshi myopathy.